文献速递头颈部肿瘤放疗消化道肿瘤放疗中枢神经肿瘤放疗

近十年某大型综合癌症中心根治性放(化)疗期间或结束后短期内死亡率分析

Mortality during or shortly after curative-intent radio-(chemo-) therapy over the last decade at a large comprehensive cancer center.
PubMed 文献 · Clin Transl Radiat Oncol · 2023-06-01

回顾某大型综合癌症中心近十年根治性放(化)疗病例,15,255 次放疗中 8,515 次(56%)为根治性,期间或放疗后 30 天内 78 例死亡(占根治性疗程 0.9%);头颈部癌 2.9%、胃肠道癌 2.4% 死亡率最高;ECOG-PS 较差与相对更早的围放疗期死亡相关(p=0.014)。

要点

  • 根治性放(化)疗期间或放疗后 30 天内死亡占全部根治性疗程的 0.9%(78/8,515)。
  • 死亡率以头颈部癌 2.9%(33/1,144)和胃肠道癌 2.4%(8/332)最高。
  • 多变量回归显示 ECOG-PS 较差与相对更早的围放疗期死亡相关(p=0.014)。

核心结论

  • 根治性放(化)疗期间或放疗后 30 天内死亡率低,但头颈部肿瘤(2.9%)和胃肠道肿瘤(2.4%)患者最高。
  • 作者认为原因包括部分癌症肿瘤快速进展、患者选择良好,其中 ECOG-PS 对避免早期死亡最有用且最有预测价值。
  • 作者提出未来研究应帮助完善围放疗期死亡率的预测因素。

研究设计与样本

  • 回顾性筛查某大型综合癌症中心近十年机构记录中接受根治性放(化)疗且在放疗期间或放疗后 30 天内死亡的患者。
  • 根治性治疗定义为单纯放疗处方剂量 EQD2 ≥ 50 Gy、放化疗 EQD2 ≥ 40 Gy。
  • 共分析 15,255 次放疗疗程,其中 8,515 次(56%)为根治性;收集人口学、疾病和治疗数据并评估。

主要发现

  • 根治性放(化)疗期间或放疗后 30 天内 78 例死亡,占全部根治性疗程的 0.9%。
  • 死亡患者中位年龄 70 岁(IQR 62-78),女性 36%(28/78)。
  • 死亡患者治疗前中位 ECOG-PS 为 1(IQR 0-2),Charlson 共病指数为 3+(IQR 2-3+)。
  • 最常见原发肿瘤为头颈部癌 42%(33/78)和中枢神经系统肿瘤 17%(13/78)。
  • 围治疗期死亡率因原发肿瘤而异,头颈部癌 2.9%(33/1,144)、胃肠道癌 2.4%(8/332)最高。

关键数值与推荐

  • 根治性单纯放疗定义为处方剂量 EQD2 ≥ 50 Gy,根治性放化疗定义为 EQD2 ≥ 40 Gy。
  • 围治疗期死亡定义为放疗期间或放疗后 30 天内死亡。
  • 死亡率按原发肿瘤分层:头颈部癌 2.9%(33/1,144),胃肠道癌 2.4%(8/332)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND INTRODUCTION: Definitive surgical, oncological and radio-oncological treatment may result in significant morbidity and acute mortality. Mortality during or shortly after treatment in patients undergoing curative radio-(chemo)-therapy has not been studied systematically. We reviewed all curative radio-(chemo-)therapies at a large comprehensive cancer center over the last decade. MATERIALS AND METHODS: The institutional record was screened for patients who received curative-intent radio-(chemo-)therapy and deceased during or within 30 days after radiotherapy. Curative therapy was defined as prescribed dosage of EQD2 ≥ 50 Gy for radiotherapy alone and EQD2 ≥ 40 Gy for radiochemotherapies. Data on demographics, disease and treatment were assembled and assessed. RESULTS: Of 15,255 radiotherapy courses delivered at our center, 8,515 (56%) were performed with curative-intent. During or within 30 days after radio-(chemo-)therapy, 78 patients died (0.9% of all curative-intent courses). Median age of the deceased patients was 70 (IQR, 62-78) years, and 36% (28/78) were female. Median pre-therapeutic ECOG-PS was 1 (IQR, 0-2) and Charlson-Comorbidity-Index was 3+ (IQR, 2-3+). The most common primary malignancies were head and neck cancer (33/78; 42%) and central nervous system tumors (13/78; 17%). Peritherapeutic mortality varied by primary tumor, with the highest prevalence observed in head and neck and gastrointestinal cancer patients with 2.9% (33/1,144) and 2.4% (8/332), respectively. Among patients with known cause of death (34/78; 44%), tumor progression (12/34; 35%) and pulmonary complications/causes (11/34; 35%) were most common. On multivariable regression analysis, a worse ECOG-PS was associated with a relatively earlier peri-radiotherapeutic death (p = 0.014). CONCLUSION: Mortality during or within 30 days of curative-intent radio-(chemo-)therapy was low, yet highest for head and neck (2.9%) and gastrointestinal tumor (2.4%) patients. Reasons for these findings include rapid tumor progression in some cancers, good patient selection, with ECOG-PS being most useful and predictive for avoiding early mortality. Future research should help refine predictors for peri-RT mortality.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Christ SM, Willmann J, Heesen P, et al. Mortality during or shortly after curative-intent radio-(chemo-) therapy over the last decade at a large comprehensive cancer center. Clin Transl Radiat Oncol. 2023. PMID: 37304171. doi:10.1016/j.ctro.2023.100645

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。